At present, the main producers of gefitinib tablets in the pharmaceutical market are AstraZeneca Pharmaceutical Co., Ltd. and Natco Pharma of India.
Clinical research data of gefitinib prove that patients with locally advanced or metastatic non-small cell lung cancer can achieve sustained and objective remission through gefitinib.
Gefitinib tablet is mainly composed of gefitinib, which is suitable for the treatment of locally advanced or metastatic non-small cell lung cancer that has received chemotherapy in the past. It is a new drug for targeted treatment of lung cancer.
Extended data:
Long-term clinical practice has proved that gefitinib is particularly effective for Asian patients due to physical reasons. Gefitinib was listed in China by a British company in 2005, and maintained its exclusive position in the domestic market for 1 1 year. The price has remained above 5,000 yuan/box for a long time, and the whole treatment cost of each patient is as high as hundreds of thousands or even hundreds of thousands.
Until the end of 20 16, after 7 years of research and development, Irecox (gefitinib tablets) produced by Qilu pharmaceutical co., ltd. was officially approved to be listed in China. At that time, the price of domestic gefitinib was more than 600 yuan per box13, which was less than that of imported drugs. In order to push down the price of anticancer drugs, so that ordinary people can afford to use good drugs, Qilu Pharmaceutical further reduced the price of Yi Rui to 498 yuan/box.
It is understood that Qilu Pharmaceutical Co., Ltd. is the first enterprise in China to list gefitinib tablets. At the end of 20 17, it became the first batch of anti-tumor drugs announced by the state, and passed the consistency evaluation of the quality and efficacy of national generic drugs.
Baidu encyclopedia-gefitinib tablets